The Startup That Wants to Regrow Your Brain's Missing Neurons
A startup just emerged from stealth with $42 million and early clinical data showing it can grow new brain cells from a patient's own blood, then implant them to restore movement in Parkinson's patients. The results from five patients are turning heads.
Imagine losing the cells in your brain that let you walk, tie your shoes, and pour a cup of coffee. That's Parkinson's disease in a nutshell. The neurons that produce dopamine (the chemical messenger controlling movement) slowly die, and no drug on the market can bring them back. Every treatment for Parkinson's today is basically a workaround: flood the brain with synthetic dopamine and hope for the best.
Oryon Cell Therapies just stepped out of the shadows with a radically different idea. What if you could grow brand-new neurons from a patient's own blood and implant them directly into the brain?
From Blood to Brain Cells
Oryon emerged from stealth on March 23 with $42 million in total funding, including a freshly closed $21 million Series A round. Investors Neuro.VC and Byers Capital led the charge. The company was quietly founded back in 2020 by Ole Isacson, M.D., Ph.D., a neuroscientist who spent three decades at Harvard and McLean Hospital studying exactly this kind of brain repair, alongside co-founder Nikola Kojic, M.D., Ph.D.
Running the show as CEO is Ron Cohen, M.D., who previously founded and led Acorda Therapeutics, a company focused on neurological diseases. Cohen has over 30 years in the space, so this isn't his first rodeo.
But the real headline isn't the money or the management team. It's the science.
The Recipe: Your Blood, Your Neurons, Your Brain
Oryon's approach works like a biological repair kit. The process starts with a simple blood draw. Scientists take those blood cells and reprogram them into something called induced pluripotent stem cells (iPSCs), which are essentially blank-slate cells that can become almost anything. Think of them as biological Play-Doh.
From there, Oryon uses proprietary methods to shape those iPSCs into A9 dopaminergic neurons, the exact subtype that dies off in Parkinson's patients. These are the cells responsible for producing dopamine in the motor control region of the brain. Once the neurons are mature, surgeons implant them into the putamen, the specific brain area where Parkinson's does its worst damage.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Because the cells come from the patient's own body, the immune system doesn't treat them as foreign invaders. That means no immune suppression drugs, which is a big deal. Organ transplant patients can tell you how brutal those medications are.
It's worth noting what makes this different from competitors. Many other cell therapy programs transplant neuronal progenitors (younger, not-yet-mature cells) and hope they finish developing after implantation. Oryon implants fully mature neurons instead. They also dose one side of the brain at a time, which lets doctors compare the treated side against the untreated side in the same patient. It's a clever built-in control group.
Five Patients, Some Jaw-Dropping Numbers
Oryon didn't just emerge with a pitch deck and a dream. They brought data, presented at the AD/PD 2026 International Conference in Copenhagen on March 21.
In their Phase 1b/2a trial, five patients received the therapy. The interim results showed motor function improvements ranging from 29% to 62% on validated assessment tools, measured between six and 18 months after treatment. Patients got better at walking, showed less rigidity, and experienced reduced bradykinesia (the frustrating slowness of movement that makes everyday tasks feel like wading through molasses).
The neuroimaging data was even more striking. Brain scans revealed significant increases in dopamine signaling in the transplanted regions. One patient showed more than a five-fold increase in dopamine activity at just six months. Several patients were able to cut back on their levodopa doses, the standard dopamine replacement drug that most Parkinson's patients depend on.
Five patients is a tiny sample, and these are interim results. Nobody should be popping champagne yet. But for a disease where the bar for "promising" is painfully low, these numbers are raising eyebrows.
A Graveyard of Good Intentions
Neurodegenerative diseases are where biotech ambitions go to die. The field's failure rate would make a venture capitalist reach for the antacids. That's not a small market, but it reflects decades of incremental improvements rather than breakthroughs.
Still, something is shifting. Investor appetite for Parkinson's and neurodegeneration broadly has picked up in recent years. In 2025 alone, about 25 neurodegenerative-focused startups collectively raised approximately $2.0 billion, averaging roughly $80.8 million per company. Korsana Therapeutics pulled in $175 million for an Alzheimer's antibody.
The pipeline is sprawling too: over 100 candidates across 80-plus companies. Approaches range from alpha-synuclein antibodies (Roche's prasinezumab is heading to Phase 3) to gene therapies, NLRP3 inflammasome inhibitors, and even AI-designed oral drugs. Oryon's autologous cell therapy sits in a category that's gaining momentum but remains surgical, expensive, and logistically complex.
Why This One Feels Different (and Why It Might Not Be)
The bull case for Oryon is straightforward: they're not masking symptoms; they're replacing what's broken. Every other Parkinson's therapy is like putting duct tape on a leaky pipe. Oryon is trying to install a new pipe.
The bear case is equally clear. Cell therapies require brain surgery, which limits how many patients you can realistically treat. Manufacturing personalized neurons from each patient's blood is expensive and time-consuming. Scaling that to thousands of patients is a problem that $42 million won't solve on its own.
Then there's the question of durability. Do these implanted neurons keep working for years, or do they eventually succumb to the same disease process that killed the originals? Eighteen months of follow-up data is encouraging, but Parkinson's is a marathon, not a sprint.
What Happens Next
Oryon plans to use its funding to finish the Phase 1b/2a trial, scale up manufacturing, and prepare for Phase 3. The company operates out of Belmont, Massachusetts, building on technology developed at Harvard and Mass General Brigham.
The path from here is long and full of potential pitfalls. But if the early data holds up in larger studies, Oryon could represent something the Parkinson's community has been waiting decades for: a therapy that doesn't just slow the decline, but actually reverses some of the damage.
For the roughly one million Americans living with Parkinson's, that possibility alone is worth watching closely.
Clinical & Regulatory4 min read
This Gene Therapy Keeps Kids Alive. The FDA Said No Once Already.
Rocket Pharmaceuticals is getting a second shot at FDA approval for Kresladi, a gene therapy that achieved 100% survival in kids with a disease that kills most of them before age two. The first rejection wasn't about science; it was about manufacturing. March 28 is decision day.
